

Exhibit I

LSD FOLLOW-UP STUDY

REPORT



OCTOBER 1980

US ARMY MEDICAL DEPARTMENT
US ARMY HEALTH SERVICES COMMAND
PROJECT DIRECTOR: LTC DAVID A. MCFARLING, MC

EXECUTIVE SUMMARY

LSD FOLLOW-UP STUDY REPORT

Because of its potential use as a chemical warfare agent, lysergic acid diethylamide (LSD) was utilized in a series of experiments by the Army Chemical Corps during the period from 1955 through 1967. Volunteer subjects for these experiments were solicited from the Army at large. As far as can be determined from the existing records, nearly all of the studies were carried out under strict medical supervision and written consent was obtained from the volunteers prior to the administration of LSD or any other agents although the specific agent(s) may not have been identified by name.

Several years after the termination of the LSD experiments in 1967, one of the test subjects contacted the Army with the information that he had been advised by his private physician that the recent onset of temporal lobe epilepsy in this subject might have been caused by his exposure to LSD some years before. Other subjects who received LSD in the same group as this individual were invited to enter Walter Reed Army Medical Center for a thorough medical and neuropsychiatric evaluation. In the meantime, growing public and congressional interest in chemical warfare testing was stimulated by the disclosure of the cases of Dr. Olson and Harold Blauer, among others. Although neither case was related to the chemical warfare experiments conducted by the Army from 1955 to 1967, there was enough concern to mandate the attempt to evaluate other individuals who had received LSD. Following a second brief evaluation project (Project 28) involving individuals who had previously requested examination, a pilot study (Project 50/50) was designed and completed in 1977. The results of this study were used to guide the design of a full-scale follow-up project. The full-scale project attempted to contact every individual for whom present addresses could be obtained and invite them to enter one of three Army medical centers for evaluation. The three centers involved were Walter Reed Army Medical Center in Washington, D.C., Dwight David Eisenhower Army Medical Center in Augusta, Georgia, and Letterman Army Medical Center in San Francisco, California. Subjects entered the hospital closest to their home residence and underwent a week-long series of studies including complete medical and neurological examinations, screening laboratory studies, electroencephalography, psychiatric interview, ophthalmology and ENT consultations, and a Halstead-Reitan Neuropsychological Test Battery. The data was collected by the central project office and entered into programmed forms for computer analysis.

Following completion of the data analysis, the pertinent findings were entered into a comprehensive report. For reasons discussed at length in that report it had become obvious in the early stages of the project that a control group with which to compare the LSD exposed subjects could not be obtained. For that reason it was necessary to adopt the much less satisfactory strategy of comparing the examined subjects with males in the general United States population in the same age range. On that basis, the medical illnesses found appeared to be similar with respect to frequency and type to that found in the comparable general population.

Likewise, the incidence of psychiatric illness was identical to that of the general population. As a group, the LSD exposed subjects appeared to be unusually well-educated, maritally stable, and economically successful. Specific concerns about the induction of seizure disorders by LSD exposure were determined to be unfounded. There was no consistent evidence of any chromosomal damage in those patients for whom chromosome studies were obtained, and except for a possible increase in the incidence of congenital heart disease in children born after paternal LSD exposure (which in any case did not exceed the national incidence of congenital heart disease) there was no suggestion of LSD-related damage in offspring of LSD subjects. Neuropsychological testing showed abnormalities in about one-third of the subjects but most of these abnormalities were borderline and 73% had probable etiologic explanations other than LSD exposure. Only 16% of the patients reported psychological symptoms occurring within a reasonable proximity to LSD exposure (defined as within two years) and most of these symptoms were benign and self-limited. Only 7% of the subjects interviewed felt that they had suffered any socioeconomic disability from their LSD exposure.

In summary, then, the majority of subjects evaluated did not appear to have sustained any significant damage from their participation in the LSD experiments; and in those cases where there were abnormalities either by history or on examination, LSD could not generally be identified conclusively as the causative agent because of the many confounding variables which could not be controlled. Chief among these were length of time having elapsed between LSD exposure and onset of symptoms, length of time having elapsed between LSD exposure and time of examination (up to 20 years), exposure to multiple other chemicals in addition to LSD, intervening adverse life circumstances, and individual motivations for seeking examination. It must be expected that similar problems would beset any study attempting to answer similar questions about exposure to chemical agents some twenty years before so that future follow-up studies of this nature are probably inadvisable from a scientific viewpoint. Nevertheless, because some subjects seem to have legitimate complaints that might reasonably be considered to have arisen from LSD exposure, such persons should continue to be afforded the opportunity to present their complaints for consideration on a case by case basis.

CONTENTS

| | <u>Page</u> |
|---|-------------|
| INTRODUCTION. | 1 |
| Background. | 1 |
| The Preliminary LSD Follow-up Projects. | 2 |
| Organization of the Final LSD Follow-up Study | 8 |
| Follow-up Examinations. | 9 |
| Data Compilation. | 11 |
| FINDINGS. | 11 |
| Subjects Evaluated. | 11 |
| Demographic Data. | 12 |
| Chemical Warfare Data | 13 |
| Deceased Subjects | 15 |
| Medical Illnesses and Laboratory Findings in Subjects Examined. | 16 |
| Congenital Abnormalities in Children of Subjects Examined | 17 |
| Halstead-Reitan Test Battery Findings | 18 |
| Adverse Reactions | 20 |
| Motivation for Participation. | 23 |
| DISCUSSION OF FINDINGS AND OBSERVATIONS | 24 |
| Review of Recognizable Limitations to Data Interpretation | 24 |
| General Medical Findings. | 27 |
| Halstead-Reitan Test Battery Findings | 30 |
| Toxicity (Acute). | 33 |
| Toxicity (Chronic). | 37 |

| | <u>Page</u> |
|---|-------------|
| Adverse Effects Reported by LSD Study Subjects. | 41 |
| A. Flashbacks. | 46 |
| B. Somatic Complaints. | 49 |
| C. Depression. | 51 |
| D. Personality Change. | 54 |
| E. Anxiety | 56 |
| F. Nightmares. | 56 |
| G. Paranoia. | 57 |
| H. Dissociative Episodes | 58 |
| I. Phobic Neurosis | 59 |
| J. Memory Loss | 59 |
| K. Illicit Drug Use. | 59 |
| L. Psychosis | 60 |
| Present Complaints. | 61 |
| Disability Resulting from LSD Exposure. | 61 |
| SUMMARY OF FINDINGS AND OBSERVATIONS. | 62 |
| BIBLIOGRAPHY. | 65 |
| CASE HISTORIES. | 116 |
| AFTERWORD: MILITARY EXPERIENCE IN PERSPECTIVE. | 151 |
| BIBLIOGRAPHY (AFTERWORD). | 157 |

TABLES

| <u>No.</u> | <u>Page</u> |
|--|-------------|
| 1. Final Status of the 741 Subjects Listed on the "LSD" Computer Roster | 72 |
| 2. Sites of Examination. | 72 |
| 3. Examinations by Project Designation | 72 |
| 4. Demographic Data (Age, Marital Status, Military Status) of 320 Subjects | 73 |
| 5. Demographic Data (Level of Education, Employment) of 320 Subjects. | 74 |
| 6. Sites of LSD Exposure | 74 |
| 7. Number of LSD Exposures per Subject | 75 |
| 8. Number of Non-LSD Exposures per Subject | 75 |
| 9. Specific Other Agents Administered to 320 Subjects. | 76 |
| 10. LSD and Chemical Warfare Exposures in the 320 Subjects. | 77 |
| 11. Exposures to Potentially Toxic Agents in 320 Subjects | 78 |
| 12. Deceased Subjects: Cause of Death, Date of Birth, Age. | 79 |
| 13. Discharge (Present) Diagnoses in Order of Frequency of the 220 LSD Follow-up Subjects Evaluated as In-Patients | 80 |
| 14. Diagnoses Listed in "Past Medical History" Portion of Narrative Summaries of In-Patient LSD Follow-up Subjects Arranged in Order of Frequency. | 83 |
| 15. Diagnosis in Order of Frequency for Subjects Responding by Medical History Questionnaire (n=100). | 86 |
| 16. Frequency of 85 Chronic Conditions in the United States, 1968-73 (DHEW Publication No. (HRA) 77-1536 Series 10-No. 109). | 88 |
| 17. Yearly Incidence of Acute Conditions in the United States from July 1968 through June 1976 (Averaged) | 91 |

| <u>No.</u> | <u>Page</u> |
|--|-------------|
| 18. Ambulatory Care Visits to Psychiatrists, 1975-76 (Source: Advance Data from Vital and Health Statistics, No. 38, DHEW 1978). | 92 |
| 19. Ambulatory Care Visits to All Specialists, 1975-76 (Source: Advance Data from Vital and Health Statistics, No. 38, DHEW 1978). | 92 |
| 20. Previous Unrecognized, Poorly Characterized or Misdiagnosed Conditions Uncovered during LSD Follow-up in 220 Subjects . | 93 |
| 21. Electroencephalographic Abnormalities (213 Reports) | 95 |
| 22. Results of Chromosome Analysis in 26 Cases. | 96 |
| 23. Results of Chromosome Analysis versus LSD or Other CW Agent Exposure. | 96 |
| 24. Reported Abnormalities in Children of LSD Subjects. | 97 |
| 25. Chi Square Values for Comparisons of Major Congenital Abnormalities | 99 |
| 26. Preliminary Results of Halstead-Reitan Neuropsychological Battery (corrected by elimination of control subjects). . . | 100 |
| 27. Motivation for Participation in In-Patient Portion of LSD Study (n=133) | 101 |
| 28. Stated Reason for Declining Participation in In-Patient Portion of LSD Study (n=96) | 101 |
| 29. Number of Doses of LSD Given to Subjects Reporting Adverse Effects | 102 |
| 30. Percentage of Subjects Receiving LSD by Number of Doses Versus Percentage of Adverse Effects Reported by Number of Doses | 102 |
| 31. Subjects Reporting Adverse Effects, LSD versus Other CW Agent Administration | 103 |
| 32. Subjects Reporting Adverse Effects, Subsequent Exposures to Non-hallucinogenic Illicit Drugs, Alcohol, Toxins. . . . | 103 |

| <u>No.</u> | | <u>Page</u> |
|------------|--|-------------|
| 33. | Comparison of Age Distribution between Total Group of LSD Follow-up Subjects and Subjects Reporting Adverse Effects. | 104 |
| 34. | Comparison of Rank at Time of LSD Experimentation with Subsequent Adverse Reactions | 105 |
| 35. | Site of Chemical Warfare Experiments and Year of Participation for Subjects Reporting Adverse Effects | 105 |
| 36. | Site of Chemical Warfare Experiments Comparing Percentage of Total Subjects Examined to Percentages of Subjects with Adverse Effects | 106 |
| 37. | Exposures to Other Chemical Warfare Agents in 31 of 76 (41%) LSD Subjects Reporting Adverse Effects | 107 |
| 38. | Toxic Exposures in 16 of 76 (21%) Subjects Reporting Adverse Effects. | 108 |
| 39. | Exposures to Toxins in Subjects Reporting Adverse Effects from LSD Exposure (arranged by case number). | 109 |
| 40. | Adverse Effects of LSD as Reported by Follow-up Subjects | 110 |
| 41. | Adverse Effects of LSD as Reported by Study Subjects (order of frequency) | 113 |
| 42. | Characteristics of Reported Flashback Phenomena. | 114 |